此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Neuromodulation of Sleep and Mood: A Multimodal Biomarker Study of Non-Invasive Vagal Nerve Stimulation (MOSAIC-VNS) (MOSAIC-VNS)

2026年11月13日 更新者:Matthew Macaluso、University of Alabama at Birmingham

The purpose of this study is to learn how non-invasive cervical transcutaneous vagus nerve stimulation (ctVNS) - a treatment given by holding a small hand-held device against the right part of your neck (cervical vagus nerve) - affects sleep, heart rhythm, mood, and certain markers in the blood and some genetic material.

The main questions it aims to answer are:

  1. Will ctVNS enhance both subjective and objective sleep continuity and regularity, improve circadian stability, and increase parasympathetic HRV indices compared with the end-of-sham baseline?
  2. Will improvements in HRV and sleep be associated with greater improvement in standardized depression ratings, with treatment effects mediated in part by improvements in sleep and in part by sleep-independent autonomic mechanisms?
  3. Will ctVNS modify the expression of miRNAs related to sleep, stress, inflammation, and neuroplasticity, and baseline or early-change miRNA profiles, combined with physiological data, and may help distinguish responders from non-responders?

This study lasts about 7 weeks.

Participants will be asked to do the following:

Visit 1/ Baseline (in person):

  • Participants will answer questions about their health, mood, and sleep;
  • have their blood pressure and pulse taken;
  • give about 28 mL (about 6 teaspoons) of blood - 20 mL for the research measurements and 8 mL for routine safety blood tests;
  • be fitted with a wrist device that measures your heart rate, physical activity and sleep; and be given the study device with training on how to use it at home.

This visit will last about 2 hours.

Weeks 1-6 (at home):

  • Participants will use the study device (nerve stimulator) twice a day (morning within 1 hour of waking, and evening within 1 hour of your usual bedtime), each use lasting about 2 minutes;
  • Participants will also need to wear the wrist device day and night;
  • Participants will fill out a short sleep diary each morning.

Visit 2/ Week 2 (in person) and Visit 3/ Week 6 (in person):

  • Participants will repeat the questionnaires and interviews from Visit 1;
  • have their blood pressure and pulse taken;
  • give another blood sample of about 20 mL;
  • have the data from their wrist device downloaded.
  • At each in-person visit after visit 1, their study device will be checked and may be exchanged for another device.

This visit will last about 1.5 - 2 hours.

The investigators will call participants on the phone to check-in at Weeks 1, 3, and 5, and a safety call at Week 7. These phone calls will last about 15 minutes.

研究概览

详细说明

Major depressive disorder (MDD) and insomnia are highly prevalent, frequently co-occur, and rank among the leading causes of disability worldwide. Up to 80% of people with MDD report significant sleep disturbance, and persistent insomnia predicts higher relapse, poorer treatment response, and greater functional impairment. Autonomic dysregulation, commonly indexed by reduced heart rate variability (HRV), is a shared feature of both conditions and a marker of poor outcome [1], alongside circadian disruption and neuroinflammatory signaling.

Cervical transcutaneous vagus nerve stimulation (ctVNS) engages vagal afferents transcutaneously and may rebalance sympathetic-parasympathetic tone [2,3] and attenuate neuroinflammatory signaling implicated in anxiety and depression [4], with downstream effects on emotion-regulatory circuits and on sleep. Despite this mechanistic plausibility, treatment response to ctVNS remains heterogeneous and mechanistically unclear, and no validated marker identifies who will benefit.

Circulating microRNAs (miRNAs) are stable, accessible post-transcriptional regulators whose peripheral profiles are altered in MDD and may track with diagnosis or relapse risk [5,6]. Preclinical evidence shows that vagus nerve stimulation, which engages the same afferent pathways as ctVNS, modulates stress- and neuroplasticity-related miRNAs (for example, miR-183-3p) [7-9]. Neural-derived exosomes (NDE) isolated from plasma are enriched for signals of neuronal origin and provide a means of interrogating brain-relevant molecular processes from a peripheral blood sample.

Neuromodulation is changing how mental and other central nervous system disorders are treated, but its clinical use is limited by an inability to predict who will respond or why. Three specific gaps slow progress: (1) the pathways linking ctVNS to improvements in sleep and depression remain unclear; (2) no study has combined continuous wearable monitoring with circulating candidate biomarkers to predict response; and (3) the relationship between autonomic change and depression improvement has not been defined.

This study addresses those gaps by combining longitudinal wearable-derived autonomic monitoring, subjective and objective sleep phenotyping, standardized clinical outcomes, and circulating neural-derived exosomal miRNA profiling within a single mechanistic framework. The design separates sleep-mediated from sleep-independent autonomic pathways underlying changes in depression.

A within-subject sham run-in was selected rather than a parallel randomized design because the aim of this pilot is within-subject signal detection and effect-size estimation rather than controlled efficacy testing. The sham run-in establishes a stable, expectancy-adjusted personal baseline and prevents carryover from active stimulation from contaminating that reference. A fixed sham-to-active order partially confounds treatment with time; this limitation is stated explicitly, is mitigated by the end-of-sham anchor and by a group-level autonomic target-engagement check, and is addressed in the planned subsequent randomized, concurrent sham-controlled trial.

Healthy reference participants (Cohort B) are enrolled not as efficacy subjects but to establish normative ranges for HRV, sleep metrics, and candidate miRNA expression, enabling interpretation of disease-related biomarker deviations.

研究类型

介入性

注册 (估计的)

40

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Alabama
      • Birmingham、Alabama、美国、35294
        • University of Alabama at Birmingham (UAB)
        • 首席研究员:
          • Matthew Macaluso, DO
        • 接触:
        • 接触:
        • 副研究员:
          • Justin Thomas, PhD
        • 副研究员:
          • Yogesh Dwivedi, PhD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 50年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • To be eligible, participants must meet all of the following criteria:

    1. Adults aged 18 through 50 years, inclusive, at the time of consent.

    2. Able to understand and provide written informed consent in English.

    3. Willing and able to wear a study-provided wrist-worn device continuously for approximately 6 weeks and to complete daily sleep diaries.

    4. Willing and able to self-administer the study device twice daily for 6 weeks and to complete a device use log.

    5. Access to a smartphone compatible with the study wearable platform, or willingness to use a study-provided device.

    6. Regular sleep opportunity of at least 6 hours per 24-hour period.

      Cohort A (symptomatic) - additional inclusion criteria:

    7. Insomnia Severity Index (ISI) total score ≥ 15 at screening and confirmed at Visit 1.

    8. MADRS total score ≥ 20 at screening and confirmed at Visit 1.

    9. Meets DSM-5-TR criteria for insomnia disorder on structured clinical interview.

    10. If receiving psychotropic medication or psychotherapy, the regimen has been stable for at least 6 weeks before Visit 1, and the participant and treating clinician agree it will remain stable through Visit 3.

      Cohort B (healthy reference) - additional inclusion criteria:

    11. ISI total score ≤ 7 and MADRS total score ≤ 8 at screening and confirmed at Visit 1.

    12. No current psychiatric disorder or sleep disorder as established by structured diagnostic interview.

    13. No psychotropic medication use within the prior 30 days.

Exclusion Criteria:

  • Participants meeting any of the following criteria are not eligible:

    1. Night-shift or rotating-shift work within the 30 days before Visit 1, or planned during participation.
    2. Travel across more than two time zones within the 14 days before Visit 1, or planned during participation.
    3. Any contraindication to cervical nVNS, including an implanted cervical electrical or metallic device, cardiac pacemaker or implantable cardioverter-defibrillator, any other implanted electronic device, clinically significant carotid atherosclerosis, prior cervical vagotomy, carotid endarterectomy, or cervical surgery at the application site.
    4. Open wound, skin breakdown, active infection, or a dermatologic condition at the intended application site.
    5. Known or suspected pregnancy, or breastfeeding. Participants of childbearing potential will undergo urine pregnancy testing at screening..
    6. Clinically significant cardiac arrhythmia, uncontrolled hypertension (systolic ≥ 160 or diastolic ≥ 100 mmHg on repeated measurement), congestive heart failure, or syncope of unclear cause.
    7. Untreated moderate-to-severe obstructive sleep apnea (STOP-Bang ≥ 5 without evaluation and clearance), restless legs syndrome requiring pharmacologic treatment, narcolepsy, or a circadian rhythm sleep-wake disorder.
    8. Moderate or severe substance or alcohol use disorder within the prior 6 months, or a positive urine drug screen for a non-prescribed substance judged to affect sleep or autonomic measures.
    9. Lifetime diagnosis of bipolar I disorder, schizophrenia, schizoaffective disorder, or another primary psychotic disorder.
    10. Active suicidal ideation with intent or plan (C-SSRS ideation type 4 or 5), any suicide attempt within the prior 6 months, or any clinical presentation requiring urgent or higher-level psychiatric care.
    11. Use of an alternative neuromodulation therapy (implanted VNS, transcranial magnetic stimulation, transcranial direct current stimulation, or electroconvulsive therapy) within the prior 3 months.
    12. Initiation of, or change in dose of, any medication with known substantial effects on heart rate variability (for example, beta-blockers, anticholinergics) within 6 weeks before Visit 1.
    13. Any medical, neurological, or psychiatric condition that, in the investigator's judgment, would compromise participant safety, adherence, or interpretation of study measures.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:非随机化
  • 介入模型:交叉作业
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
假比较器:Sham Run-In (Weeks 1-2)

Inactive sham stimulation, twice daily. Each participant receives first.

sham run-in ctVNS

有源比较器:Active stimulation (Weeks 3-6)

Blinded active cervical nVNS, twice daily. Each participant receives second.

ctVNS

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Primary physiologic endpoint as change in parasympathetic heart rate variability (nocturnal RMSSD).
大体时间:Change from Visit 2 (week 2) to Visit 3 (week 6).

Linear mixed-effects models estimating within-subject physiologic change from the end-of-sham anchor (week 2), with participant as a random effect and phase, time, cohort, age, sex, and body mass index as fixed effects.

Change from Visit 2 (week 2) to Visit 3 (week 6).
Primary clinical endpoint as change in Insomnia Sleep Index (ISI) total score in Cohort A (affected).
大体时间:Change from Visit 2 (week 2) to Visit 3 (week 6).

The ISI is a 7-item self-report questionnaire used to assess nature, severity and impact of insomnia over previous 2 weeks. Each item is rated 0-4 , with total score range of 0-28. Higher score indicates greater insomnia severity. Response is defined as ≥ 50% reduction in ISI total score or remission (ISI ≤ 7).

Change from Visit 2 (week 2) to Visit 3 (week 6).

次要结果测量

结果测量
措施说明
大体时间
Change in Montgomery-Asberg Depression Rating Scale (MADRS) total score in Cohort A (affected) from Visit 2 to Visit 3.
大体时间:Change from Visit 2 (week 2) to Visit 3 (week 6).

The MADRS is a 10-item clinician rated scale used to assess severity of depression symptoms. Each item is scored from 0 to 6, with total possible score range of 0-60. A total score of 0-8 indicates no depression, and 8 or above would indicate some level of depression ranging from mild to severe. Higher score indicates greater depression symptoms.

Change from Visit 2 (week 2) to Visit 3 (week 6).
Differential expression of neural-derived exosomal microRNAs from Visit 2 to Visit 3.
大体时间:Change from Visit 2 (week 2) to Visit 3 (week 6).

Differential expression screening with Benjamini-Hochberg false discovery rate control (q < 0.05), followed by exploratory penalized regression classifiers with nested cross-validation and reporting of optimism-corrected performance.

Change from Visit 2 (week 2) to Visit 3 (week 6).

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Matthew Macaluso, DO、University of Alabama at Birmingham

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2028年9月30日

研究完成 (估计的)

2029年1月1日

研究注册日期

首次提交

2026年10月16日

首先提交符合 QC 标准的

2026年11月13日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月13日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • STUDY00000060
  • TEAMSCI9617 (其他赠款/资助编号:UAB Heersink School of Medicine (Team Science Award))

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅